Literature DB >> 10638577

Comparative, open, randomized trial of the efficacy and tolerance of slow-release 5-ASA suppositories once daily versus conventional 5-ASA suppositories twice daily in the treatment of active cryptogenic proctitis: French Pentasa Study Group.

P Marteau1, C Florent.   

Abstract

OBJECTIVE: The efficacy and tolerance of slow-release 5-ASA suppositories (Pentasa 1 g/day) were compared with those of conventional 5-ASA suppositories (Rowasa 0.5 g b.i.d.).
METHODS: Two hundred and fifty-one (251) patients presenting with an exacerbation of cryptogenic proctitis were randomized. Clinical activity and rectal lesions were measured at days 1 and 14 (and at day 21 for patients not in remission at day 14), and each patient had to fill out a daily diary card (checklist).
RESULTS: Results are given for slow-release and classical suppositories, respectively. The reduction in symptoms and lesions was identical in both groups. Treatment was continued until day 21 in 36% versus 33% of the patients, and minor or moderate side effects occurred in 5.6% versus 6.3% (NS). The tolerance of the suppositories was rated as satisfactory every day by 77% versus 54% (p = 0.001), and early suppository expulsion occurred in 0.5% versus 3.4% (p = 0.001).
CONCLUSIONS: The treatments were equally effective and both were well tolerated. However, the advantages of the slow-release suppositories were that patients exhibited greater tolerance and early expulsion was less frequent.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10638577     DOI: 10.1111/j.1572-0241.2000.01679.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  5 in total

1.  New Research in Ulcerative Colitis: Optimizing 5-ASA Administration for Efficacy and Adherence.

Authors:  Charles A Sninsky
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-01

2.  Ulcerative proctitis.

Authors:  Charles B Whitlow
Journal:  Clin Colon Rectal Surg       Date:  2004-02

3.  A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg Twice daily in patients with active mild-to-moderate ulcerative proctitis.

Authors:  Mark Lamet
Journal:  Dig Dis Sci       Date:  2010-07-30       Impact factor: 3.199

Review 4.  When disease extent is not always a key parameter: Management of refractory ulcerative proctitis.

Authors:  Georgios Michalopoulos; Konstantinos Karmiris
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-12-11

5.  Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents.

Authors:  Melvin B Heyman; Jaroslaw Kierkus; Jean Spénard; Hadia Shbaklo; Monique Giguere
Journal:  Inflamm Bowel Dis       Date:  2010-11       Impact factor: 5.325

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.